CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
pregabalin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01637077
NCT01637077Phase 2Completed

RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome

Academic and Community Cancer Research United·interventional·Posted Jul 10, 2012·Updated Apr 6, 2018

In Brief

A Phase 2 clinical trial evaluating pregabalin, placebo, and 1 other intervention for Pain and Peripheral Neuropathy. Completed, enrolled 46 participants across 6 sites.

Detailed Summary

This randomized pilot clinical trial studies pregabalin in preventing acute pain syndrome in patients receiving paclitaxel. Pregabalin may control the pain caused by cancer treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 10, 2012
Enrollment StartJan 1, 2012
Primary CompletionNov 1, 2013
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.0 years ago

Interventions

pregabalindrug

Given PO

placebodrug

Given PO

questionnaire administrationother

Ancillary studies